Related Experiment Video

Updated: Jun 15, 2026

Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

9.7K

Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers

Jason K Sa1,2,3, Jae Ryoung Hwang4, Young-Jae Cho5

  • 1Institute for Refractory Cancer Research, Samsung Medical Center, Seoul, Republic of Korea.

Genome Biology
|November 28, 2019
PubMed
Abstract

Insights

This study explores gynecologic tumor genomics and drug responses, identifying TP53 mutations and ID2 expression as biomarkers for targeted therapies like PARP inhibitors, paving the way for precision cancer medicine.

Area of Science:

  • Oncology
  • Genomics
  • Pharmacology

Background:

  • Gynecologic malignancies are a major cause of mortality in women globally.
  • Genomic complexity and pathway activation contribute to treatment failures in gynecologic cancers.
  • Patient-tailored treatment requires integrating molecular tumor characterization with drug response data.

Purpose of the Study:

  • To establish a pharmacogenomic library of gynecologic tumors.
  • To explore drug sensitivities and identify predictive biomarkers.
  • To advance precision medicine for gynecologic cancers.

Main Methods:

  • Genomic and pharmacological annotation of 139 gynecologic tumors (epithelial ovarian cancers, cervical, endometrial, uterine sarcomas).
  • Pharmacogenomic association analysis against 37 molecularly targeted drugs.
  • Identification of lineage-specific drug sensitivities and molecular determinants.

Main Results:

  • Discovered lineage-specific drug sensitivities in gynecologic tumors.
  • Identified TP53 mutation as a determinant for poly (ADP-Ribose) polymerase (PARP) inhibitor response.
  • Found inhibitor of DNA binding 2 (ID2) transcriptome expression as a potential predictive biomarker for olaparib treatment.

Conclusions:

  • Rapid drug screening combined with genomic profiling shows utility for precision gynecologic cancer treatment.
  • Biomarker identification supports the development of targeted therapeutic strategies.
  • This approach can guide patient-tailored treatment regimens for improved outcomes.
Keywords:
Gynecologic malignancyID2PARP inhibitorPharmacogenomic analysisTP53 mutations

More Related Videos

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing09:24

Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing

Published on: June 9, 2016

9.4K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...